Purpose: To examine differences in effects according to growth hormone (GH) treatment duration in adult GH-deficient patients. Methods: In the Italian cohort of the observational Hypopituitary Control and Complications Study, GH-treated adults with GH deficiency (GHD) were grouped by duration of treatment; ≤ 2 years (n = 451), > 2 to ≤ 6 years (n = 387) and > 6 years (n = 395). Between-group differences in demographics, medical history, physical characteristics, insulin-like growth factor-I standard deviation score (IGF-I SDS) and lipid profile at baseline, last study visit and changes from baseline to last study visit were assessed overall, for adult- and childhood-onset GHD and by gender using ANOVA for continuous variables and Chi-squared test for categorical variables. Results: At baseline, treatment duration groups did not differ significantly for age, gender, body mass index, GHD onset, IGF-I SDS, lipid profile, and quality of life. Mean initial GH dose did not differ significantly according to treatment duration group in any subgroup, except female patients, with highest mean dose seen in the longest duration group. In the longest duration group for patients overall, adult-onset patients and male patients, there were significant decreases in GH dose from baseline to last visit, and in total and low-density lipoprotein (LDL)-cholesterol concentrations. IGF-I SDS increased, to a greater extent, in the longest duration group for patients overall and female patients. Conclusions: The results show that long-term GH treatment is associated with decreasing GH dose, increased IGF-I, decreased LDL-cholesterol and the presence of surrogate markers that help to give confidence in a diagnosis of GHD.

Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) / Rochira, V.; Mossetto, G.; Jia, N.; Cannavo, S.; Beck-Peccoz, P.; Aimaretti, G.; Ambrosio, M. R.; Di Somma, C.; Losa, M.; Ferone, D.; Lubrano, C.; Scaroni, C.; Giampietro, A.; Corsello, S. M.; Poggi, M.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 41:11(2018), pp. 1259-1266. [10.1007/s40618-018-0860-x]

Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS)

Rochira, V.
Conceptualization
;
2018-01-01

Abstract

Purpose: To examine differences in effects according to growth hormone (GH) treatment duration in adult GH-deficient patients. Methods: In the Italian cohort of the observational Hypopituitary Control and Complications Study, GH-treated adults with GH deficiency (GHD) were grouped by duration of treatment; ≤ 2 years (n = 451), > 2 to ≤ 6 years (n = 387) and > 6 years (n = 395). Between-group differences in demographics, medical history, physical characteristics, insulin-like growth factor-I standard deviation score (IGF-I SDS) and lipid profile at baseline, last study visit and changes from baseline to last study visit were assessed overall, for adult- and childhood-onset GHD and by gender using ANOVA for continuous variables and Chi-squared test for categorical variables. Results: At baseline, treatment duration groups did not differ significantly for age, gender, body mass index, GHD onset, IGF-I SDS, lipid profile, and quality of life. Mean initial GH dose did not differ significantly according to treatment duration group in any subgroup, except female patients, with highest mean dose seen in the longest duration group. In the longest duration group for patients overall, adult-onset patients and male patients, there were significant decreases in GH dose from baseline to last visit, and in total and low-density lipoprotein (LDL)-cholesterol concentrations. IGF-I SDS increased, to a greater extent, in the longest duration group for patients overall and female patients. Conclusions: The results show that long-term GH treatment is associated with decreasing GH dose, increased IGF-I, decreased LDL-cholesterol and the presence of surrogate markers that help to give confidence in a diagnosis of GHD.
13-mar-2018
41
11
1259
1266
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) / Rochira, V.; Mossetto, G.; Jia, N.; Cannavo, S.; Beck-Peccoz, P.; Aimaretti, G.; Ambrosio, M. R.; Di Somma, C.; Losa, M.; Ferone, D.; Lubrano, C.; Scaroni, C.; Giampietro, A.; Corsello, S. M.; Poggi, M.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - 41:11(2018), pp. 1259-1266. [10.1007/s40618-018-0860-x]
Rochira, V.; Mossetto, G.; Jia, N.; Cannavo, S.; Beck-Peccoz, P.; Aimaretti, G.; Ambrosio, M. R.; Di Somma, C.; Losa, M.; Ferone, D.; Lubrano, C.; Scaroni, C.; Giampietro, A.; Corsello, S. M.; Poggi, M.
File in questo prodotto:
File Dimensione Formato  
083_Rochira_et_al_JEI_2018.pdf

Open access

Descrizione: Fulltext of the article
Tipologia: Versione pubblicata dall'editore
Dimensione 699.95 kB
Formato Adobe PDF
699.95 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1168904
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact